Claims

1. Use of N-(2-(6-fluoro-1H-indol-3-yl)ethyl)-3-(2,2,3,3-tetrafluoropropoxy) benzylamine (idalopirdine) and an acetylcholinesterase inhibitor selected from the group consisting of donepezil and rivastigmine in the manufacture of a medicament for the treatment of Parkinson's disease, wherein the treatment of Parkinson's disease is selected from the group consisting of reducing falls in a patient with Parkinson's disease, improving low gait speed in a patient with Parkinson's disease, reducing movement stoppages in a patient with Parkinson's disease, reducing freezing gait in a patient with Parkinson's disease, and improving gait control in a patient with Parkinson's disease.

2. The use according to claim 1, wherein, when the acetylcholinesterase inhibitor is donepezil, the dose of donepezil is from 1 to 30 mg, such as from 5 to 23 mg; wherein the acetylcholinesterase inhibitor is rivastigmine, the dose of rivastigmine is from 1 to 20 mg.

3. The use according to any of claims 1 to 2, wherein the daily dose of idalopirdine is from 10 mg to 120 mg, such as from 10 mg to 100 mg, such as from 30 mg to 90 mg, such as from 30 mg to 60 mg.

4. The use according to any of claims 1 to 3, wherein the acetylcholinesterase inhibitor is donepezil.

5. The use according to any of claims 1 to 4, wherein the treatment is for reducing falls in a patient with Parkinson's disease.

6. The use according to any of claims 1 to 4, wherein the treatment is for improving low gait speed in a patient with Parkinson's disease.

7. The use according to any of claims 1 to 4, wherein the treatment is for reducing movement stoppages in a patient with Parkinson's disease.

8. The use according to any of claims 1 to 4, wherein the treatment is for reducing freezing gait in a patient with Parkinson's disease.

9. The use according to claim 8, wherein the freezing gait is of less than about 2 seconds.

10. The use according to any of claims 1 to 4, wherein the treatment is for improving gait control in a patient with Parkinson's disease.